BIOMEDICAN Enters the Global Astaxanthin Market Through Its Patented Biosynthesis Platform
Dec 2, 2020
BIOMEDICAN, a biotech company designing patented low-cost methods of growing high-value compounds at scale with proprietary yeasts, has entered the Astaxanthin market to diversify products outside of Cannabinoids. This new development allows BIOMEDICAN's biosynthesis platform to target any high-value compound and significantly disrupt the current technologies.
Astaxanthin is a widely used, high-value compound known as a powerful antioxidant and anti-inflammatory. The Astaxanthin market consists of three main segments: fish feed, animal feed, and human consumption. Astaxanthin's value is growing astronomically: its market was worth over $1 billion in 2019 and is projected to be worth $3.3 billion by 2027.
BIOMEDICAN has developed a biosynthesis process that produces the purest form of Astaxanthin, which is non-GMO and organic. This process is 90% less expensive than producing the chemical synthetic form of Astaxanthin, which is being sold into the animal feed market. Chemical synthetics cannot be used for human consumption.
"We believe our high-quality, non-GMO, organic Astaxanthin will significantly disrupt the animal feed and human consumption market," says BIOMEDICAN CEO Maxim Mikheev. "The large buyers for fish farms and cattle feed are currently using a chemical synthetic and desperately want to get out of the synthetic market. Our product offers them the ideal solution at same price as they are paying for chemical synthetics."
BIOMEDICAN has been able to produce Astaxanthin in less than six months, which shows that it can biosynthesize high-value compounds quickly and still produce a high-quality, low-cost product. The company has significant interest from the largest buyers in the market and continues to build interest internationally.
"Our biosynthesis platform can target any compound that has a sizable market and significantly disrupt it," states BIOMEDICAN President Dennis O'Neill. "We are doing bioavailability tests for the two largest buyers of Astaxanthin in the world, and we expect to receive tens of millions of dollars in orders next year."
About BIOMEDICAN
BIOMEDICAN is a biosynthesis platform focused on scientific, cannabinoids, therapeutics, and other high-value compounds. The company produces pharmaceutical-grade, bioidentical, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. BIOMEDICAN's patented low-cost methods of growing high-value compounds at scale with proprietary yeasts increases purity and reduces production costs by 70-90%.
BIOMEDICAN's current focus is the production of high-value compounds and cannabinoids for the treatment of pain, anxiety, obesity, brain disorders, and other significant indications. BIOMEDICAN's team of expert PhD scientists has a proven track record of patenting and developing manufacturing technologies for high-purity compounds using biosynthesis and genetics.
For more information, go to www.biomedican.com Dennis O'Neill President [email protected]
Contact Info
Jon Lindsay Phillips
RLM PR
[email protected]
+1-646-828-8566
This news release may include forward-looking statements including opinions, assumptions, estimates and the Company's assessment of future plans and operations
Any financial outlook and future-oriented financial information contained in this document regarding prospective financial performance, financial position or cash flows is based on assumptions about future events, including economic conditions and proposed courses of action based on management's assessment of the relevant information that is currently available. Projected operational information contains forward-looking information and is based on a number of material assumptions and factors, as are set out above. These projections may also be considered to contain future-oriented financial information or a financial outlook. The actual results of the Company's operations for any period will likely vary from the amounts set forth in these projections and such variations may be material. Actual results will vary from projected results. Readers are cautioned that any such financial outlook and future-oriented financial information contained herein should not be used for purposes other than those for which it is disclosed herein.
The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.
Press Release Service by Newswire.com
Original Source: BIOMEDICAN Enters the Global Astaxanthin Market Through Its Patented Biosynthesis Platform
More News
At Summit, Xi Sought to Tilt Trump’s Stance on America’s Place in Asia
In his talks with President Trump, the Chinese leader used praise, warnings and wartime history to challenge American support for Taiwan and Japan.
A Tetris-Like Maze Blocks Protests in Pakistan’s Capital
Pakistani authorities have barricaded Islamabad with more than 1,500 shipping containers to stop opposition protesters, choking off access to the capital.
Suicide bombing at police checkpoint in Pakistan kills at least 11
A suicide bomber detonated an explosives-laden vehicle at a roadside police checkpoint in northwestern Pakistan on Saturday, killing at least 11 people and wounding about 30 others, officials said, in a sign of increasing violence in the region bordering Afghanistan. The attack occurred in Dera Ismail Khan, a district in Khyber Pakhtunkhwa province, said Bilal Faizi, a spokesman for the provincial emergency service. Local police chief Safdar Baloch said most of those killed and wounded were...
Thailand’s Bangkok declares flood disaster across city as thousands flee from homes
Entire Bangkok neighbourhoods were inundated on Saturday as the city government declared a flood disaster after the worst rains in years overwhelmed the Thai capital, submerging roads, cars and forcing thousands to leave their homes. Bangkok is flood-prone, especially during the monsoon season, but waters rarely linger for long. Nonetheless, the city’s drainage is notoriously ill-equipped to handle storm bursts as it struggles to cope with waters that have reached at least two feet (60cm) and...
How Chinese firms can avoid a Europe-style backlash in Southeast Asia
China’s technology companies face a question that no pricing strategy can answer: what will their success do to their trading partners? In Europe, that question has become politically urgent. European Commission President Ursula von der Leyen warns of a “second China shock”, linking persistent trade imbalances to the erosion of Europe’s industrial base. Europe’s dispute carries a broader warning: affordable products can coexist with deep anxiety over the loss of productive capability. If...
How Alibaba is using AI to revamp its mapping app – and take on Meituan
Late last year, Zhang Xuan’s small beef noodle joint in Shanghai suddenly began seeing a dramatic surge in orders. Sales over the past few months have been 50 to 60 per cent higher than normal, he estimates. The driver? The new Street Stars feature on Chinese tech giant Alibaba Group Holding’s Amap mapping app, which listed Zhang’s eatery as the fourth best restaurant in Shanghai’s Changning district. Prominently displayed on Amap’s main page, the system uses artificial intelligence to rate...
Why Pakistan’s endless war on militants fails to break the cycle
For over two decades, Pakistan has waged countless counterterrorism campaigns against Taliban and Baloch insurgents in its western regions bordering Afghanistan and Iran, yet remains mired in a cycle of violence it cannot break. Scores of soldiers, policemen and civilians are killed every month in Pakistan’s northwestern Khyber Pakhtunkhwa and southwestern Balochistan provinces, where near-daily attacks on security personnel, government officials and other prominent figures are carried out by...
A Tetris-Like Maze Blocks Protests in Pakistan’s Capital
Pakistani authorities have barricaded Islamabad with more than 1,500 shipping containers to stop opposition protesters, choking off access to the capital.
China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts
Chinese biotech deal making is moving beyond the licensing of individual drug candidates, as the country transforms from a follower to a global innovation leader, according to analysts. The latest transaction underscores that shift. Beijing-based cancer drug developer InnoCare Pharma said on Thursday that it had entered into a strategic research collaboration and licensing agreement with US pharmaceutical giant Eli Lilly that could be worth up to US$3.35 billion. InnoCare said it would use its...
Thailand has had enough of foreign tourists behaving badly
At a zoo a short drive south of Bangkok, Charoon Youngprapakorn has spent a lifetime taking the pulse of Thailand’s tourism industry from an unlikely vantage point: the open jaws of crocodiles. Handlers at his Samut Prakan Crocodile Farm & Zoo have long thrilled onlookers by coaxing tips from the audience and carefully placing the money into the mouths of animals capable of taking off an entire hand. The crocodiles at this open-air, fan-cooled throwback to 1980s showmanship still take their tips...
Flyovers and Pandas Masked Divides in Trump and Xi’s U.S.-China Summit
President Trump pressed his personal brand of diplomacy as President Xi Jinping of China made his first trip to the White House in more than a decade.
Dining With A.I. Moguls, Billionaires and Xi Jinping, Trump Went Off Script
Altman. Musk. Huang. Bezos. They all came to the White House Thursday night, though you might not have seen it on TV.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.